Table 1 Patient demographics and baseline charactersitics (n = 129)
Characteristics | N (%) |
|---|---|
Median age (range), years | 63 (34 - 86) |
Median time from diagnosis to PLD (range), years | 5.9 (0.1 - 26.7) |
Distribution of metastasis | |
Bone | 84 (65) |
Liver | 59 (46) |
Lymph node | 54 (42) |
Lung | 48 (37) |
Skin and sof tissue | 42 (33) |
Pleura | 30 (23) |
Abdominal* | 16 (12) |
Brain | 8 (6) |
Others+ | 7 (5) |
Metastatic sites involved | |
One | 19 (15) |
Two | 54 (42) |
Three | 26 (20) |
Four or more sites | 30 (23) |
Cardiac risk factors | |
Prior anthracycline therapy | 77 (60) |
Age > 60 years | 74 (57) |
Hypertension | 50 (39) |
Prior thoracic irradiation† | 39 (30) |
History of cardiac disease | 35 (27) |
Median number of cardiac risk factors (range) | 2 (1 - 5) |
Previous therapies, setting | |
None | 4 (3) |
Endocrine, adjuvant | 66 (51) |
Endocrine, metastatic | 84 (65) |
Endocrine (adjuvant and/or metastatic) | 95 (74) |
Chemotherapy, adjuvant | 77 (60) |
Chemotherapy, metastatic | 99 (77) |
Chemotherapy (adjuvant and/or metastatic) | 117 (91) |
Anthracycline containing (adjuvant and/or metastatic) | 77 (60) |
Taxane containing (adjuvant and/or metastatic) | 73 (57) |
Trastuzumab-containing (adjuvant/metastatic) | 14 (11) |
PLD line of chemotherapy‡ | |
First | 12 (9) |
Second | 32 (25) |
Third | 28 (22) |
Fourth and higher | 57 (44) |
Median number of PLD cycles (range)§ | 6 (1-6) |
Median cumulative PLD dose, mg/m2 (range) § | 210 (25 - 300) |